by Peter Ciszewski | Sep 13, 2018
The US Food and Drug Administration (FDA) approved a subcutaneous formulation of tocilizumab (Actemra, Genentech) for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. “Systemic juvenile idiopathic arthritis is a...
by Peter Ciszewski | Sep 12, 2018
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid, a skin disorder characterized by large blisters. Although the blisters are usually located on the arms, legs, or middle of the body, in...
by Peter Ciszewski | Sep 11, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Barry Greene, President of Alnylam, discusses the growth of the biotech industry in Cambridge. MA.
by Peter Ciszewski | Sep 10, 2018
Greg Duncan, President and Chief Executive Officer of Celtaxsys, provides an overview of his company and it’s focus on cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system of about 70,000 children and adults...
by Peter Ciszewski | Sep 10, 2018
Investigators at the UC Davis MIND Institute and NeuroPointDX, a division of Stemina Biomarker Discovery, have identified a group of blood metabolites that could help detect some children with autism spectrum disorder (ASD). Part of the Children’s Autism...
